HealthTree.org

Outlet metrics

Domain Authority

Ranking

Global

#357650

United States

#90782

Health/Health Conditions and Concerns

#195

Traffic sources

Monthly visitors

Articles

A Father-Daughter Story of Hope and Resilience

3 weeks ago | healthtree.org | Ruth Fein

It was January 2024, and Paola had recently finished medical school. She was just settling into her new job at a San Diego company dedicated to advancing multiple myeloma research. Then the call came from her parents. “Dad was feeling really bad,” she remembers. “He had a pain in his chest, and I told them to go to the ER, thinking that it was probably a heart attack.” In fact, it was a lesion in his rib. A biopsy at the El Paso, Texas, hospital near where they lived revealed it was multiple myeloma.
IMS 2024: New Myeloma Immunotherapy Strategies

Oct 9, 2024 | healthtree.org | Jennifer Ahlstrom

Immunotherapy continues to be an expanding field in myeloma care with an overwhelming amount of development happening in the space, according to several experts at the International Myeloma Society (IMS) meeting hosted last week in Rio de Janeiro, Brazil. During the conference, Ajai Chari, MD, from the University of California at San Francisco (UCSF), reviewed the vast number of ongoing and upcoming products for CAR T and bispecific antibodies that aim to extend remissions for myeloma patients.
IMS 2024: News for High-Risk Multiple Myeloma

Oct 7, 2024 | healthtree.org | Jennifer Ahlstrom

Despite major advancements in myeloma care over the past decade, a quarter of newly diagnosed myeloma patients survive less than three years, according to presentations at the International Myeloma Society (IMS) meeting held last week in Rio de Janeiro, Brazil.
Myeloma News: HealthTree at the 2024 IMS Meeting

Oct 4, 2024 | healthtree.org | Jennifer Ahlstrom

The HealthTree team is back from Rio de Janeiro, Brazil, where we attended the 21st annual meeting of the International Myeloma Society (IMS) last week! This leading conference brought together myeloma experts from around the globe to discuss cutting-edge research, treatments, and the unmet needs of the myeloma community. The educational sessions were packed with valuable information, covering all stages of myeloma and providing an overview of the most recent data.
When Does Smoldering Myeloma Turn Active Myeloma?

Aug 27, 2024 | healthtree.org | Jennifer Ahlstrom

Smoldering myeloma is a precursor stage of multiple myeloma that lies between an earlier condition called monoclonal gammopathy of undetermined significance (MGUS) and active multiple myeloma. Until treatment side effects become completely benign, it is critical for doctors to assess the likelihood of progression to know who will and won't progress in order to treat those who need it most.
What Are Neutrophils in Myeloma?

Aug 19, 2024 | healthtree.org | Jennifer Ahlstrom

What are Neutrophils? What are neutrophils, and why do they matter if you have multiple myeloma? Neutrophils are the most common type of white blood cells (50-70%) and are the first line of defense against injury or infections. Neutrophils block, disable, or digest invading particles and microorganisms. They constantly survey the body for signs of infection and quickly trap and kill pathogens. They also talk to other cells to signal the body to mount an immune response or to help heal damaged cells.
T Cell Exhaustion in Myeloma: Causes and Solutions

Aug 15, 2024 | healthtree.org | Jennifer Ahlstrom

Understanding T-Cell Exhaustion: A Barrier in Cancer TreatmentYour T cells are part of the body's extensive immune system, designed to find and attack a host of diseases, including viruses, bacterial infections, and cancer. But what happens when your T cells become too tired to fight? And why does that happen? With a growing body of active research in immunotherapy and a large number of patients who don't respond to these treatments, these are critical questions to answer.
Myeloma Updates from ASCO and EHA 2024

Jul 10, 2024 | healthtree.org | Jennifer Ahlstrom

Several studies presented at the 2024 ASCO meeting showed that using four-drug combination therapies helped newly diagnosed myeloma patients achieve lower disease burden as measured by minimal residual disease (MRD) and longer remissions (progression-free survival). Additionally, the CD38 monoclonal antibodies are helping to close the gap between fit and unfit patients.
Salt Lake City Cure Tour with Dr. Douglas Sborov

Jun 6, 2024 | healthtree.org | Jennifer Ahlstrom

On July 2nd, join us for our in-person SLC Cure Tour workshop to learn more about HealthTree and the HealthTree Cure Hub – a powerful, free tool that helps you manage your disease and contribute to cures. Dr. Douglas Sborov from Huntsman Cancer Institute will be on hand to talk about potential causes of blood clot prevention and the use of CAR-T in older patients. He will discuss their work in myeloma and blood cancers, new ways patients can participate in research, and answer your questions.
Belantamab shows positive data in myeloma

Jun 5, 2024 | healthtree.org | Jennifer Ahlstrom

Belantamab mafodotin (Blenrep, GSK) appears to be a phoenix rising from the ashes with positive data from two multiple myeloma clinical trials presented at this week's recent American Society of Clinical Oncology (ASCO) meeting. (What is the ASCO conference?) Blenrep was granted FDA accelerated approval on August 5, 2020, based on results from the DREAMM-2 clinical trial. The FDA required GlaxoSmithKline (GSK) to provide confirmatory data in order to receive full approval.